<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412024000600267</article-id>
<article-id pub-id-type="doi">10.24245/gom.v92i6.9659</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Vacuna nonavalente contra el virus del papiloma humano: una estrategia para prevenir el cáncer de cuello uterino]]></article-title>
<article-title xml:lang="en"><![CDATA[Nonavalent vaccine against human papillomavirus: a strategy to prevent cervical cancer.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Anaya Rodríguez]]></surname>
<given-names><![CDATA[Andrés Felipe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Clínica FOSCAL  ]]></institution>
<addr-line><![CDATA[Bucaramanga Santander]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>92</volume>
<numero>6</numero>
<fpage>267</fpage>
<lpage>273</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412024000600267&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412024000600267&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412024000600267&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES: El cáncer de cuello uterino es un problema de salud pública debido a su alta incidencia. Su causa principal es el virus del papiloma humano trasmitido por contacto sexual. Una herramienta de prevención es la inmunización. En la actualidad existen tres vacunas; de ellas, la nonavalente es la más reciente.  OBJETIVO: Investigar la bibliografía reciente y describir los desenlaces con la aplicación de la vacuna nonavalente a pacientes con cáncer de cuello uterino.  METODOLOGÍA: Búsqueda de artículos en la base de datos Pubmed con el descriptor &#8220;nonavalente&#8221; y los términos MeSH &#8220;vacuna recombinante nonavalente contra el virus del papiloma humano&#8221;, &#8220;vacunas contra el virus del papiloma humano&#8221; y &#8220;cáncer de cuello uterino&#8221;; lo anterior con las reacciones adversas, efectividad y repercusión de la vacuna nonavalente contra el cáncer de cuello uterino.  RESULTADOS: Se encontraron 107 artículos de los que se excluyeron 80 por duplicados, títulos confusos y resúmenes incompletos, sin aporte de datos referentes al estudio. Al final, solo se analizaron 27 fuentes.  CONCLUSIONES: La vacuna nonavalente tiene alcance en contra de cinco genotipos de alto riesgo: más que otras vacunas. Es efectiva contra las enfermedades provocadas por el virus del papiloma humano, incluidas las neoplasias intraepiteliales cervicales y el cáncer de cuello uterino. Además, tiene un perfil de seguridad similar al de las vacunas predecesoras, aunque su efectividad está ligada a otros factores.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND: Cervical cancer is a public health problem due to its high incidence. Its main cause is the human papillomavirus transmitted by sexual contact. One prevention tool is immunization. At present there are three vaccines, the nonavalent is the most recent.  OBJECTIVE:  To investigate the recent literature and describe the findings with the application of the nonavalent vaccine in patients with cervical cancer.  METHODOLOGY:  Search of articles in the Pubmed database with the descriptor &#8220;nonavalent&#8221; and the MeSH terms &#8220;recombinant nonavalent human papillomavirus vaccine&#8221;, &#8220;human papillomavirus vaccines&#8221; and &#8220;cervical cancer&#8221;; the above with adverse reactions, effectiveness and impact of the nonavalent vaccine against cervical cancer.  RESULTS:  We found 107 articles of which 80 were excluded due to duplicates, confusing titles and incomplete abstracts, without providing data related to the study. In the end, only 27 sources were analyzed.  CONCLUSIONS:  The nonavalent vaccine has reach against five high-risk genotypes; more than other vaccines. It is effective against diseases caused by human papillomavirus, including cervical intraepithelial neoplasia and cervical cancer. In addition, it has a safety profile similar to that of its predecessor vaccines, although its effectiveness is linked to other factors.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Vacuna nonavalente contra el virus del papiloma humano]]></kwd>
<kwd lng="es"><![CDATA[cáncer de cuello uterino]]></kwd>
<kwd lng="es"><![CDATA[efectividad]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="en"><![CDATA[human papillomavirus nonavalent vaccine]]></kwd>
<kwd lng="en"><![CDATA[uterine cervical cancer]]></kwd>
<kwd lng="en"><![CDATA[effectivity]]></kwd>
<kwd lng="en"><![CDATA[security]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harden]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Munger]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus molecular biology]]></article-title>
<source><![CDATA[Mutat Res - Rev Mut Res]]></source>
<year>2017</year>
<volume>772</volume>
<page-range>3-12</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gravitt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history of HPV infection across the lifespan: role of viral latency]]></article-title>
<source><![CDATA[Viruses]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>267</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[SV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review]]></article-title>
<source><![CDATA[Clin Sci]]></source>
<year>2017</year>
<volume>131</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2201-21</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buskwofie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[David-West]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Clare]]></surname>
<given-names><![CDATA[CA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of Cervical Cancer: Incidence and Disparities]]></article-title>
<source><![CDATA[J Natl Med Assoc]]></source>
<year>2020</year>
<volume>112</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>229-32</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Awolude]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cervical cancer worldwide]]></article-title>
<source><![CDATA[Curr Probl Cancer]]></source>
<year>2018</year>
<volume>42</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>457-65</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yousefi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Aria]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ghaedrahmati]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bakhtiari]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Update on human papilloma virus vaccines: History, types, protection and efficacy]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2022</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aranda-Flores]]></surname>
<given-names><![CDATA[CE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infección por el virus del papiloma humano en varones]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2015</year>
<volume>83</volume>
<page-range>697-706</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazcano-Ponce]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Salmerón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention and control of neoplasms associated with HPV in high-risk groups in Mexico City: The Condesa Study]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2018</year>
<volume>60</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>703-12</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Marzan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Armaos]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cervical cancer: an overview of pathophysiology and management]]></article-title>
<source><![CDATA[Semin Oncol Nurs]]></source>
<year>2019</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>166-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durham]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Ndeffo-Mbah]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Skrip]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[National and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States]]></article-title>
<source><![CDATA[Proc Natl Acad Sci USA]]></source>
<year>2016</year>
<volume>113</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>5107-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boiron]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Joura]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Largeron]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Prager]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria]]></article-title>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2016</year>
<volume>16</volume>
<page-range>153</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forster]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Waller]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Taking stock and looking ahead: Behavioural science lessons for implementing the nonavalent human papillomavirus vaccine]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2016</year>
<volume>62</volume>
<page-range>96-102</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riethmuller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jacquard]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Lacau St Guily]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aubin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France]]></article-title>
<source><![CDATA[BMC Public Health]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>453</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Alemany]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso de Ruiz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tous]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries Brazil, Mexico, India and China]]></article-title>
<source><![CDATA[Cancer Epidemiology]]></source>
<year>2014</year>
<volume>38</volume>
<page-range>748-56</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egli-Gany]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Spaar Zographos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Diebold]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Masserey Spicher]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2019</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>111</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inturrisi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lissenberg-Witte]]></surname>
<given-names><![CDATA[BI]]></given-names>
</name>
<name>
<surname><![CDATA[Veldhuijzen]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bogaards]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2021</year>
<volume>148</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>320-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Capra]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giovannelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Matranga]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bellavia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2017</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1839-43</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petry]]></surname>
<given-names><![CDATA[KU]]></given-names>
</name>
<name>
<surname><![CDATA[Bollaerts]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bonanni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine]]></article-title>
<source><![CDATA[Hum Vaccin Immunother]]></source>
<year>2018</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1800-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mariani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Preti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cristoforoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stigliano]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of the benefits and potential issues of the nonavalent HPV vaccine]]></article-title>
<source><![CDATA[Int J Gynaecol Obstet]]></source>
<year>2017</year>
<volume>136</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>258-65</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Hutubessy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chaiyakunapruk]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of cost-effectiveness studies of human papillomavirus HPV vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2018</year>
<volume>36</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2529-44</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chesson]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Laprise]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Brisson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Markowitz]]></surname>
<given-names><![CDATA[LE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus HPV vaccine among US females previously vaccinated with 4-Valent HPV Vaccine]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2016</year>
<volume>213</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1694-700</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopalco]]></surname>
<given-names><![CDATA[PL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spotlight on the 9-valent HPV vaccine]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2017</year>
<volume>11</volume>
<page-range>35-44</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahumud]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gow]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michaeli]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Stoycheva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marcus]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV Vaccination in South Africa]]></article-title>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2022</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>333-43</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2019</year>
<volume>9</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phua]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[HCW]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jit]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore]]></article-title>
<source><![CDATA[Vaccine]]></source>
<year>2022</year>
<volume>39</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>2255-63</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naslazi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hontelez]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
<name>
<surname><![CDATA[Naber]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[van Ballegooijen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The differential risk of cervical cancer in HPV-vaccinated and -unvaccinated women: a mathematical modeling study]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2021</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>912-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De la Fuente]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aguado]]></surname>
<given-names><![CDATA[JJH]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Boix]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain]]></article-title>
<source><![CDATA[Human Vaccines &amp; Immunotherapeutics]]></source>
<year>2019</year>
<volume>15</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>1949-61</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simms]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Kitchener]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2016</year>
<volume>139</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2771-80</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joura]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Iversen]]></surname>
<given-names><![CDATA[OE]]></given-names>
</name>
<name>
<surname><![CDATA[Bouchard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>711-23</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toh]]></surname>
<given-names><![CDATA[ZQ]]></given-names>
</name>
<name>
<surname><![CDATA[Kosasih]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Garland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus]]></article-title>
<source><![CDATA[Infect Drug Resist]]></source>
<year>2019</year>
<volume>12</volume>
<page-range>1951-67</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Logroño]]></surname>
<given-names><![CDATA[IEN]]></given-names>
</name>
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[ACC]]></given-names>
</name>
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[LGC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la vacuna nonavalente en la prevención de la infección por virus papiloma humano HPV y cáncer cervical]]></article-title>
<source><![CDATA[La Ciencia al Servicio de la Salud]]></source>
<year>2019</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>30-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kharbanda]]></surname>
<given-names><![CDATA[EO]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez-Benitez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[DeSilva]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Naleway]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes]]></article-title>
<source><![CDATA[JAMA Netw Open]]></source>
<year>2021</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
